Fig. 5.
Fig. 5. Exposure of PS, CD36, and band 3 peptide 3d on normal-, PS–exposing-, or sickle RBCs. / Normal untreated RBCs (Normal), RBCs treated with 0.5 mmol/L CaCl2, and 2 μmol/L A23187 (PS), or sickle RBCs (SS) were labeled with annexin V-FITC (solid bars), or with MAb OKM5 against CD36 (striped bars) or 1F4 against band 3 peptide 3d (shaded bars) and subsequently with antimouse/PE, and analyzed by FACS. The percentage of cells in the population positive for either of these surface markers are indicated as percentage of gated events. *Indicates significant differences by the Student t test from normal RBC labeling. Error bars depict the standard error; n = 4.

Exposure of PS, CD36, and band 3 peptide 3d on normal-, PS–exposing-, or sickle RBCs.

Normal untreated RBCs (Normal), RBCs treated with 0.5 mmol/L CaCl2, and 2 μmol/L A23187 (PS), or sickle RBCs (SS) were labeled with annexin V-FITC (solid bars), or with MAb OKM5 against CD36 (striped bars) or 1F4 against band 3 peptide 3d (shaded bars) and subsequently with antimouse/PE, and analyzed by FACS. The percentage of cells in the population positive for either of these surface markers are indicated as percentage of gated events. *Indicates significant differences by the Student t test from normal RBC labeling. Error bars depict the standard error; n = 4.

Close Modal

or Create an Account

Close Modal
Close Modal